MedTrace Logo

Effect of Age on the Renal Clearance of Adefovir

NCT00187746 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2012-11-21

No results posted yet for this study

Summary

Healthy African American subjects with normal hepatic and renal function will be administered 10mg adefovir dipivoxil in a fasting state. Subjects will have blood and urine collections over the following 24 hours for the measurement of adefovir renal clearance. To investigate the role of age in renal adefovir elimination, 8 subjects will be enrolled from each of the following age groups: 18-25 years and 48-55 years.

Conditions

  • Other Conditions That May Be A Focus of Clinical Attention

Interventions

DRUG

Adefovir dipivoxil

Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil

Sponsors & Collaborators

Principal Investigators

  • Kathleen Giacomini, PhD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187746 on ClinicalTrials.gov